SiBone (NASDAQ:SIBN) CFO Anshul Maheshwari Sells 5,005 Shares

SiBone (NASDAQ:SIBN - Get Free Report) CFO Anshul Maheshwari sold 5,005 shares of the business's stock in a transaction that occurred on Wednesday, July 2nd. The shares were sold at an average price of $18.34, for a total transaction of $91,791.70. Following the transaction, the chief financial officer directly owned 217,078 shares of the company's stock, valued at approximately $3,981,210.52. This represents a 2.25% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Anshul Maheshwari also recently made the following trade(s):

• On Monday, May 19th, Anshul Maheshwari sold 2,424 shares of SiBone stock. The stock was sold at an average price of $19.48, for a total transaction of $47,219.52.
• On Friday, May 16th, Anshul Maheshwari sold 9,585 shares of SiBone stock. The shares were sold at an average price of $19.76, for a total transaction of $189,399.60.
• On Monday, May 12th, Anshul Maheshwari sold 4,937 shares of SiBone stock. The stock was sold at an average price of $19.02, for a total transaction of $93,901.74.
• On Wednesday, May 7th, Anshul Maheshwari sold 4,937 shares of SiBone stock. The shares were sold at an average price of $17.00, for a total transaction of $83,929.00.

SiBone Stock Performance

Shares of SiBone stock traded up $0.34 on Thursday, reaching $18.78. 294,940 shares of the company were exchanged, compared to its average volume of 393,604. The company has a debt-to-equity ratio of 0.21, a quick ratio of 7.26 and a current ratio of 8.53. The company's 50-day moving average is $18.17 and its two-hundred day moving average is $16.29. The firm has a market cap of $800.40 million, a price-to-earnings ratio of -29.34 and a beta of 0.93. SiBone has a 1-year low of $11.70 and a 1-year high of $20.05.

SiBone (NASDAQ:SIBN - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.24) by $0.09. The business had revenue of $47.29 million for the quarter, compared to the consensus estimate of $45.13 million. SiBone had a negative return on equity of 16.00% and a negative net margin of 15.03%. As a group, research analysts expect that SiBone will post -0.78 earnings per share for the current fiscal year.

Institutional Investors Weigh In On SiBone

Several hedge funds and other institutional investors have recently made changes to their positions in SIBN. ANTIPODES PARTNERS Ltd acquired a new stake in shares of SiBone in the first quarter valued at about $34,000. Virtus Fund Advisers LLC bought a new stake in SiBone during the fourth quarter worth $40,000. GAMMA Investing LLC increased its holdings in SiBone by 20,352.6% in the 1st quarter. GAMMA Investing LLC now owns 3,886 shares of the company's stock worth $55,000 after purchasing an additional 3,867 shares in the last quarter. Virtus Advisers LLC acquired a new position in SiBone in the 1st quarter worth about $58,000. Finally, KLP Kapitalforvaltning AS bought a new position in SiBone during the 4th quarter worth $97,000. 98.11% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have issued reports on SIBN. Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 target price on shares of SiBone in a research note on Tuesday, May 6th. Needham & Company LLC reaffirmed a "buy" rating and set a $24.00 target price on shares of SiBone in a research note on Tuesday, May 6th. Finally, Truist Financial upped their target price on SiBone from $20.00 to $22.00 and gave the company a "buy" rating in a report on Tuesday, May 6th.

SiBone Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.